{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T05:24:25Z","timestamp":1695360265013},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T00:00:00Z","timestamp":1536710400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00277-018-3488-1","type":"journal-article","created":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T08:29:27Z","timestamp":1536740967000},"page":"143-150","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China"],"prefix":"10.1007","volume":"98","author":[{"given":"Yan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tienan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junling","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huacong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,12]]},"reference":[{"issue":"8","key":"3488_CR1","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1023\/A:1008418727472","volume":"9","author":"A L\u2019opez-Guillermo","year":"1998","unstructured":"L\u2019opez-Guillermo A, Cid J, Salar A et al (1998) Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. classification. Ann Oncol 9(8):849\u2013855","journal-title":"Ann Oncol"},{"issue":"7","key":"3488_CR2","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/cncr.20531","volume":"101","author":"F Morabito","year":"2004","unstructured":"Morabito F, Gallamini A, Stelitano C, Callea V, Guglielmi C, Neri S, Lazzaro A, Orsucci L, Ilariucci F, Sacchi S, Vitolo U, Federico M (2004) Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi. Cancer 101(7):1601\u20131608","journal-title":"Cancer"},{"issue":"4","key":"3488_CR3","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/10428190290016926","volume":"43","author":"M Reiser","year":"2002","unstructured":"Reiser M, Josting A, Soltani M, Staib P, Salzberger B, Diehl V, Engert A (2002) T-cell non-Hodgkin\u2019s lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. Leuk Lymphoma 43(4):805\u2013811","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"3488_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3324\/haematol.10737","volume":"92","author":"HT Arkenau","year":"2007","unstructured":"Arkenau HT, Chong G, Cunningham D, Watkins D, Sirohi B, Chau I, Wotherspoon A, Norman A, Horwich A, Matutes E (2007) Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 92(2):271\u2013272","journal-title":"Haematologica"},{"issue":"2","key":"3488_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/cncr.27733","volume":"119","author":"D Mahadevan","year":"2013","unstructured":"Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, LeBlanc M, Fisher RI, Miller TP (2013) Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: southwest oncology group study S0350. Cancer 119(2):371\u2013379","journal-title":"Cancer"},{"issue":"6","key":"3488_CR6","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1046\/j.1365-2141.2003.04226.x","volume":"120","author":"I Chau","year":"2003","unstructured":"Chau I, Harries M, Cunningham D, Hill M, Ross PJ, Archer CD, Norman AR, Wotherspoon A, Koh DM, Gill K, Uzzell M, Prior Y, Catovsky D (2003) Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin\u2019s and non-Hodgkin\u2019s lymphoma. Br J Haematol 120(6):970\u2013977","journal-title":"Br J Haematol"},{"issue":"11","key":"3488_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1634\/theoncologist.2014-0305","volume":"19","author":"TM Kim","year":"2014","unstructured":"Kim TM, Kim DW, Kang YK et al (2014) A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I\/II extranodal natural killer\/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer study group. Oncologist 19(11):1\u20132","journal-title":"Oncologist"},{"issue":"15","key":"3488_CR8","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","volume":"120","author":"YL Kwong","year":"2012","unstructured":"Kwong YL, Kim WS, Lim ST et al (2012) SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy fromthe Asia Lymphoma Study Group. Blood 120(15):2973\u20132980","journal-title":"Blood"},{"issue":"2","key":"3488_CR9","first-page":"441","volume":"23","author":"YL Li","year":"2015","unstructured":"Li YL (2015) Clinical efficacy of dexamethasone, methotrexate combined with cyclophosphamide for treatment of patients with peripheral T-cell lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 23(2):441\u2013444","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"6","key":"3488_CR10","first-page":"9374","volume":"8","author":"G Yao","year":"2015","unstructured":"Yao G, Zhou D, Zhou M, Bao C, He D, Li L, Zhu J, He J, Shi J, Zheng W, Cai Z, Huang H, Ye X, Xie W (2015) Clinical analysis and prognostic significance of L-asparaginase containing multidrug chemotherapy regimen in incipient peripheral T-cell lymphoma. Int J Clin Exp Med 8(6):9374\u20139383","journal-title":"Int J Clin Exp Med"},{"issue":"1","key":"3488_CR11","first-page":"3909","volume":"32","author":"Y Shao","year":"2014","unstructured":"Shao Y, Guan M, Chen S et al (2014) Topotecan combined with Ifosfamide, etoposide, and L-asparaginase (TIEL) regimen improves outcomes in aggressive T-cell lymphoma. Med Oncol 32(1):3909\u20133905","journal-title":"Med Oncol"},{"issue":"1","key":"3488_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00280-005-0136-y","volume":"58","author":"JG Kim","year":"2006","unstructured":"Kim JG, Sohn SK, Chae YS, Kim DH, Baek JH, Lee KB, Lee JJ, Chung IJ, Kim HJ, Yang DH, Lee WS, Joo YD, Sohn CH (2006) CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 58(1):35\u201339","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"3488_CR13","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1016\/S2352-3026(18)30039-5","volume":"5","author":"M Gleeson","year":"2018","unstructured":"Gleeson M, Peckitt C, To YM et al (2018) CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Lancet Haematol 5(5):e190\u2013e200","journal-title":"Lancet Haematol"},{"issue":"1","key":"3488_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11899-018-0431-4","volume":"13","author":"D Chihara","year":"2018","unstructured":"Chihara D, Oki Y (2018) Central nervous system involvement in peripheral T cell lymphoma. Curr Hematol Malig Rep 13(1):1\u20136","journal-title":"Curr Hematol Malig Rep"},{"issue":"6","key":"3488_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1080\/10245332.2016.1264163","volume":"22","author":"W Wei","year":"2017","unstructured":"Wei W, Wu P, Li L, Zhang Z-H (2017) Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer\/T-cell lymphoma. Hematology 22(6):320\u2013329","journal-title":"Hematology"},{"issue":"17","key":"3488_CR16","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","volume":"48","author":"SJ Kim","year":"2012","unstructured":"Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ, Lee J, Ryoo BY, Ko YH, Huh J, Yang WI, Kim HK, Min SK, Lee SS, Do IG, Suh C, Kim WS, Consortium for Improving Survival of Lymphoma (CISL) investigators (2012) Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer 48(17):3223\u20133231","journal-title":"Eur J Cancer"},{"issue":"11","key":"3488_CR17","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00277-015-2468-y","volume":"94","author":"B-B Park","year":"2015","unstructured":"Park B-B, Kim WS, Suh C, Shin DY, Kim JA, Kim HG, Lee WS (2015) Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. Ann Hematol 94(11):1845\u20131851","journal-title":"Ann Hematol"},{"issue":"2","key":"3488_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00277-016-2877-6","volume":"96","author":"F Qi","year":"2017","unstructured":"Qi F, Dong M, He X, Li Y, Wang W, Liu P, Yang J, Gui L, Zhang C, Yang S, Zhou S, Shi Y (2017) Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified. Ann Hematol 96(2):245\u2013251","journal-title":"Ann Hematol"},{"issue":"1","key":"3488_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.clml.2012.09.002","volume":"13","author":"MH Voss","year":"2013","unstructured":"Voss MH, Lunning MA, Maragulia JC, Papadopoulos EB, Goldberg J, Zelenetz AD, Horwitz SM (2013) Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with Hepatosplenic T-cell lymphoma: a single institution experience. Clinical Lymphoma, Myeloma and Leukemia 13(1):8\u201314","journal-title":"Clinical Lymphoma, Myeloma and Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3488-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3488-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3488-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T19:09:16Z","timestamp":1568228956000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3488-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,12]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["3488"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3488-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,12]]},"assertion":[{"value":"16 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}